Current guidelines recommend endocrine treatment with aromatase inhibitors (AIs) in post-menopausal women with hormone receptor-positive breast cancer. Musculoskeletal symptoms are commonly reported with AI treatment,however, we do not have consistent methods to measure these symptoms prospectively. This gap in our knowledge inhibits the ability to test and develop treatments for AI-associated musculoskeletal symptoms. This pilot study will evaluate functional tests and standardized instruments for their ability to prospectively assess musculoskeletal symptoms in women being treated with AIs for breast cancer.
Specific Aims: 1) identify a core set of instruments for measuring musculoskeletal symptoms, 2) model the time course and predictors of change in musculoskeletal symptoms, 3) explore the effect of musculoskeletal symptoms on adherence to AIs in women during the first 6 months of AI treatment. Methods: We will prospectively assess musculoskeletal symptoms due to treatment with aromatase inhibitors. Post-menopausal women beginning AI treatment for hormone responsive breast cancer will be invited to join this study.
Study Type
OBSERVATIONAL
Enrollment
150
Observational study
North Memorial Medical Center
Robbinsdale, Minnesota, United States
Park Nicollet Institute
Saint Louis Park, Minnesota, United States
Identify a core set of instruments for measuring musculoskeletal symptoms
Time frame: 09/2011
Model the time course and predictors of change in musculoskeletal symptoms
Time frame: 09/2011
Explore the effects of musculoskeletal symptoms on adherence to AIs in women during the first 6 months of AI treatment
Time frame: 09/2011
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.